Antimicrobial Stewardship: The Role of *In Vitro* Diagnostics

Doris-Ann Williams
Chief Executive

*IVDs: Transforming Patient Pathways*
What is BIVDA?

• National industry association for manufacturers and distributors of IVDs in the UK
• Represent over 100 members from the IVD industry
• Members range from start-up companies to UK subsidiaries of multinational corporations
IVDs and AMR

- Importance of IVDs in tackling the AMR challenge cannot be overstated
- This is because the use of modern diagnostic testing (in the lab or at the point-of-care), to direct antibiotic prescribing, has several benefits:
  - Reduce **time** to appropriate treatment decision
  - Reduce the **use** of broad-spectrum antibiotics
  - Reduce possible **side-effects** of unnecessarily aggressive antibiotics
Case studies using CRP

Many studies have been done in the UK, regarding the use of C-Reactive Protein to determine prescription of antibiotics in primary care. Been introduced across Wales.

CRP has been shown to reduce community prescription by up to 40% in some countries

Barriers – cost, perception of time, engineering into practice

Case study 1 - 42yo man with persistent illness
Case Study 2 - 23yo woman with sudden illness
Case Study 3 - 28yo man with communication issues
UK Industry launched a declaration in November this year during Antibiotic Awareness Week (13-19 November)

Called for:

• Designated funding
• Re-Promotion of AMR
Next Steps

• Through the AMR Working Party, industry is continuing to work together to call for:
  - Greater **uptake** of **existing** diagnostics
  - **Implementation** of the O’Neill Review
  - **Education** of the **public** about the role of IVDs
  - **Identification** and **adoption** of best AMR practice across the NHS
Contact Us

• enquiries@bivda.co.uk
• @BIVDA
• www.bivda.co.uk

IVDs: Transforming Patient Pathways